透過您的圖書館登入
IP:44.200.27.215
  • Journals
  • OpenAccess

Control of Blood Glucose with Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes Mellitus

Abstracts


Aims/Introduction. This study aimed to assess glucose control and treatment satisfaction in a real-world setting, specifically of add-on therapy with SGLT2 inhibitors in type 2 diabetes mellitus (T2DM) patients in Taiwan. Methods. Forty-one T2DM patients who had a glycated hemoglobin (HbA1c) level of >7% and were receiving oral antidiabetic drugs were enrolled. SGLT2 inhibitors were administered for 24 weeks. All treatment choices and medical instructions were at physician's discretion to reflect real-life practice. Results. SGLT2 inhibitor therapy was associated with a decrease in HbA1c and fasting blood glucose levels, decreased body weight, and improved treatment satisfaction. A 6-month course of SGLT2 inhibitors maintained adequate glucose control and considerably improved beta-cell function. Conclusion. The present study showed that desired glucose control improved with oral antidiabetes therapy, including SGLT2 inhibitors for 6-month intervals in cases of poorly controlled T2DM. A 6-month course of SGLT2 inhibitor therapy maintained adequate glucose control and considerably improved beta-cell function.

Read-around